Related Experiment Video
Updated: May 1, 2026

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
Sonic hedgehog signaling is active in human adrenal cortex development and deregulated in adrenocortical tumors
Débora C Gomes1, Letícia F Leal, Livia M Mermejo
1School of Medicine (D.C.G., L.F.L., L.M.M., C.A.S., C.E.M., L.G.T., S.T., F.R., A.C.M., L.N.R., M.C., S.R.R.A.), Ribeirao Preto Medical School-University of Sao Paulo, 14090-900 Ribeirao Preto, Brazil; School of Medicine (M.C.B.V.F., A.C.L.), University of Sao Paulo, 01246-903 Sao Paulo, Brazil; and Boldrini Children's Center (J.A.Y., S.R.B., I.A.C., M.J.M.), 13083-210 Campinas, Brazil.
Background:
The sonic hedgehog (SHH) pathway plays a key role in rodent adrenal cortex development and is involved in tumorigenesis in several human tissues, but data in human adrenal glands are limited.
Objectives:
The objectives of the study were to analyze the involvement of the SHH pathway in human adrenal development and tumorigenesis and the effects of SHH inhibition on an adrenocortical tumor (ACT) cell line.
Patients And Methods:
Expression of SHH pathway components was evaluated by immunohistochemistry in 51 normal adrenals (33 fetal) and 34 ACTs (23 pediatric) and by quantitative PCR in 81 ACTs (61 pediatric) and 19 controls (10 pediatric). The effects of SHH pathway inhibition on gene expression and cell viability in the NCI-H295A adrenocortical tumor cell line after cyclopamine treatment were analyzed.
Results:
SHH pathway proteins were present in fetal and postnatal normal adrenals and showed distinct patterns of spatiotemporal expression throughout development. Adult adrenocortical carcinomas presented with higher expression of PTCH1, SMO, GLI3, and SUFU compared with normal adult adrenal cortices. Conversely, pediatric ACTs showed lower mRNA expression of SHH, PTCH1, SMO, GLI1, and GLI3 compared with normal pediatric adrenal cortices. In vitro treatment with cyclopamine resulted in decreased GLI3, SFRP1, and CTNNB1 mRNA expression and β-catenin staining as well as decreased cell viability.
Conclusions:
The SHH pathway is active in human fetal and postnatal adrenals, up-regulated in adult adrenocortical carcinomas, and down-regulated in pediatric ACTs. SHH pathway antagonism impaired cell viability. The SHH pathway is deregulated in ACTs and might provide a new target therapy to be explored.
Insights
The Sonic Hedgehog (SHH) pathway is active in human adrenal development and deregulated in adrenocortical tumors (ACTs). SHH pathway inhibition reduced tumor cell viability, suggesting it as a potential therapeutic target.
Area of Science:
- Endocrinology
- Developmental Biology
- Oncology
Background:
- The Sonic Hedgehog (SHH) pathway is crucial for adrenal cortex development in rodents and implicated in human tumorigenesis.
- Limited data exists on SHH pathway involvement in human adrenal gland development and cancer.
Purpose of the Study:
- To investigate the role of the SHH pathway in human adrenal development and adrenocortical tumors (ACTs).
- To assess the impact of SHH pathway inhibition on an ACT cell line.
Main Methods:
- Immunohistochemistry and quantitative PCR were used to analyze SHH pathway component expression in normal adrenal glands and ACTs (pediatric and adult).
- The NCI-H295A ACT cell line was treated with cyclopamine to evaluate SHH inhibition effects on gene expression and cell viability.
Main Results:
- SHH pathway proteins exhibited specific spatiotemporal expression patterns during human adrenal development.
- Adult adrenocortical carcinomas showed increased expression of PTCH1, SMO, GLI3, and SUFU compared to normal adult adrenals.
- Pediatric ACTs displayed decreased mRNA expression of SHH, PTCH1, SMO, GLI1, and GLI3 compared to normal pediatric adrenals.
- Cyclopamine treatment reduced GLI3, SFRP1, and CTNNB1 mRNA expression, β-catenin staining, and cell viability in vitro.
Conclusions:
- The SHH pathway is active in human adrenal development and shows differential regulation in ACTs (up-regulated in adult, down-regulated in pediatric).
- SHH pathway antagonism demonstrated anti-proliferative effects on ACT cells.
- The SHH pathway is a deregulated pathway in ACTs and represents a potential therapeutic target.
Related Concept Videos
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
Cushing Syndrome II: Pathophysiology
Hormones of the Adrenal Glands
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and...
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Hypothalamic-Pituitary Axis

